Related by context. All words. (Click for frequent words.) 76 nonsmall cell lung cancer 73 unresectable stage 72 stage IIIb IV 72 IV NSCLC 72 recurrent NSCLC 71 squamous histology 71 metastatic renal cell carcinoma 71 metastatic renal cell 71 stage IIIB 70 non squamous 70 metastatic bladder 69 metastatic gastric 69 nonmetastatic 69 completely resected 68 HER2 positive metastatic breast 68 stage IIIb 68 Stage IIIb 68 non squamous NSCLC 68 EGFR mutation positive 68 refractory metastatic 67 medically inoperable 67 TTF Therapy 67 relapsed MM 67 squamous non 67 pancreatic adenocarcinoma 67 metastatic renal 67 metastatic GIST 67 unresectable 67 recurrent metastatic 67 pancreatic NET 67 stage IIIA 67 malignant pleural mesothelioma 67 relapsed SCLC 67 gemcitabine chemotherapy 66 recurrent glioblastoma multiforme 66 standard chemotherapy regimen 66 advanced medullary thyroid 66 underwent resection 66 recurrent glioblastoma 66 Folfox 66 cisplatin chemotherapy 66 fallopian tube carcinoma 66 preoperative chemotherapy 66 Hepatocellular Carcinoma HCC 66 advanced epithelial ovarian 66 taxane therapy 66 metastatic colorectal 66 mitoxantrone plus 66 Stage IIB 66 Allovectin 7 ® 65 gefitinib Iressa 65 gastrointestinal stromal tumors 65 FOLFOX4 65 systemic ALCL 65 refractory CLL 65 metastatic HER2 positive 65 KRAS mutations occur 65 metastatic pancreatic 65 metastatic hormone refractory 65 gemcitabine carboplatin 65 IV melanoma 65 biliary tract cancer 65 leukemia AML 65 metastatic RCC 65 metastatic pancreatic cancer 65 Bayer HealthCare Onyx Pharmaceuticals 65 erlotinib Tarceva ® 65 resistant hormone refractory 65 metastatic kidney 65 relapsed GBM 65 5 fluorouracil leucovorin 65 concurrent chemoradiation 65 prostate cancer CRPC 65 Jevtana 65 dacarbazine DTIC 65 underwent liver transplantation 65 pegylated interferon alpha 65 tumors GIST 65 metastatic castration resistant 65 heavily pretreated 65 antiretroviral naïve 65 axitinib 65 metastatic lung cancer 64 advanced hepatocellular carcinoma 64 IV metastatic melanoma 64 basal cell carcinoma BCC 64 lymphoid malignancies 64 sorafenib Nexavar 64 irinotecan chemotherapy 64 unresectable tumors 64 Surgical resection 64 Canvaxin TM 64 taxane chemotherapy 64 advanced unresectable 64 neoadjuvant therapy 64 pediatric acute lymphoblastic 64 HBeAg negative 64 BRAF V# mutation 64 unresectable recurrent 64 peritoneal carcinomatosis 64 differentiated thyroid 64 IV malignant melanoma 64 Amrubicin 64 oral clodronate 64 sorafenib Nexavar ® 64 Lung transplantation 64 ZACTIMA 64 clinically localized prostate 64 Bayer Nexavar 64 refractory colorectal cancer 64 imatinib Gleevec ® 64 castrate resistant 64 hormone refractory 64 docetaxel Taxotere ® 64 BRCA deficient 64 autoantibody positive 64 Peginterferon alfa 2b 64 histologically confirmed 63 T1c 63 AML acute myeloid 63 untreated AML 63 hepatitis C genotype 63 Pemetrexed 63 mCRPC 63 metastatic castrate resistant 63 chemotherapeutic regimens 63 squamous cell lung cancer 63 temsirolimus 63 relapsed ovarian cancer 63 docetaxel chemotherapy 63 chemotherapy cisplatin 63 Doxil ® 63 advanced metastatic prostate 63 cytoreduction 63 mRCC 63 castrate resistant prostate cancer 63 unresectable Stage III 63 Aflibercept 63 Pfizer Sutent 63 liver metastases 63 receptor tyrosine kinase inhibitor 63 low dose cytarabine 63 heavily pretreated patients 63 Stage IIIB IV 63 dasatinib Sprycel 63 decompensated liver disease 63 CYT# potent vascular disrupting 63 humanised monoclonal antibody 63 visceral metastases 63 advanced NSCLC 63 Median survival 63 ErbB2 positive 63 refractory NSCLC 63 regorafenib 63 pegylated liposomal doxorubicin 63 pancreatic neuroendocrine tumors 63 Medullary thyroid cancer 63 previously untreated follicular 63 taxane refractory 63 Allovectin 7 63 metastatic medullary thyroid 63 Tarceva erlotinib 63 forodesine 63 placebo dexamethasone 63 HNSCC 63 trastuzumab DM1 63 FOLFIRI alone 63 lintuzumab SGN 63 paclitaxel Taxol R 63 anthracycline taxane 63 Renal Cell Carcinoma RCC 63 commercialize deforolimus 63 Canvaxin 63 endocrine therapies 63 relapsed CLL 63 advanced metastatic renal 63 HRPC ovarian cancer 63 Roche Herceptin 63 refractory ovarian cancer 63 metastatic malignant melanoma 63 anthracyclines taxanes 62 plus gemcitabine 62 Glioblastoma Multiforme 62 paclitaxel Taxol ® 62 mCRC patients 62 prostate cancer HRPC 62 underwent surgical resection 62 recurrent GBM 62 unresectable liver cancer 62 plus dacarbazine 62 radiation chemoradiation 62 adjuvant cisplatin 62 leukemia ALL 62 smoldering myeloma 62 recurrent glioblastoma multiforme GBM 62 haematologic malignancies 62 refractory AML 62 NSCLC 62 cyclophosphamide chemotherapy 62 Temodar ® 62 Alemtuzumab 62 Cloretazine 62 metastatic malignant 62 unresectable locally advanced 62 seminoma 62 standard chemotherapy regimens 62 relapsed leukemia 62 eribulin 62 MabThera Rituxan 62 Stage IIIb IV 62 gastrointestinal stromal tumor GIST 62 histologies 62 Nexavar sorafenib 62 relapsing remitting MS RRMS 62 Adjuvant chemotherapy 62 Temsirolimus 62 trabectedin 62 dacarbazine chemotherapy 62 LHRH receptor positive 62 hormone refractory metastatic prostate 62 refractory chronic lymphocytic 62 rituximab refractory 62 Waldenstrom macroglobulinemia 62 BR.# 62 colorectal cancer liver metastases 62 resectable 62 Hormone Refractory Prostate Cancer 62 peritoneal cancer 62 Flu Cy 62 dasatinib Sprycel ® 62 Velcade bortezomib 62 hepatocellular cancer 62 minimally symptomatic 62 Platinol ® cisplatin 62 papillary renal cell carcinoma 62 nonsquamous 62 cediranib 62 demonstrated antitumor activity 62 gastrointestinal stromal tumors GIST 62 TTR amyloidosis 62 relapsed multiple myeloma 62 nonsquamous histology 62 untreated metastatic pancreatic 62 cisplatin gemcitabine 62 oral Hycamtin 62 relapsing MS 62 Acute myeloid leukemia 62 FOLFIRINOX 62 recurrent colorectal cancer 62 PSMA ADC 62 refractory acute myeloid 62 HGS ETR1 62 trastuzumab Herceptin R 62 evaluating REVLIMID 62 biochemical relapse 62 refractory chronic myeloid 62 cabazitaxel 62 Lilly Gemzar 61 hematological malignancy 61 indolent follicular non 61 OvaRex ® MAb 61 estramustine 61 RRMS patients 61 YONDELIS 61 KRAS wild 61 relapsed ALL 61 evaluating tivozanib 61 paclitaxel carboplatin 61 anthracycline containing 61 sorafenib tablets 61 Naive Patients 61 Amgen Neulasta ® 61 leukemia APL 61 EGFR TKI 61 BRIM2 61 null responder HCV 61 eribulin mesylate 61 OvaRex 61 Sanofi Aventis Taxotere 61 adriamycin 61 oblimersen 61 INSPIRE Trial Phase III 61 HyperAcute 61 vinca alkaloid 61 vandetanib 61 acute leukemias 61 PROSTVAC VF 61 cilengitide 61 ZOLINZA 61 non resectable 61 KRAS mutations 61 pegylated interferon alfa 2a 61 leukemia multiple myeloma 61 PD LID 61 lumiliximab 61 Chronic lymphocytic leukemia 61 non splenectomized 61 dirucotide MBP# 61 non metastatic osteosarcoma 61 Gleevec resistant 61 alemtuzumab treated 61 neoadjuvant treatment 61 metastatic HRPC 61 platinum refractory 61 chronic myeloid 61 deCODE ProstateCancer TM 61 oral ridaforolimus 61 medullary thyroid cancer 61 dacarbazine 61 palliative radiotherapy 61 treatment naïve genotype 61 virus HCV infection 61 Hodgkin lymphoma HL 61 MAGE A3 ASCI 61 Paraplatin ® carboplatin 61 Fludara ® 61 chronic HCV genotype 61 allogeneic stem cell 61 IMiDs 61 FluCAM 61 samalizumab 61 FOLFOX6 61 evaluating picoplatin 61 Gemzar ® 61 intra arterial chemotherapy 61 infusional 5-FU/LV 61 renal carcinoma 61 Gleevec imatinib mesylate 61 cytotoxic therapy 61 neoadjuvant radiation 61 pegylated alpha interferon 61 RSR# 61 sunitinib malate 61 Daclizumab 61 docetaxel Taxotere R 61 relapsed acute lymphoblastic 61 FluCAM arm 61 iniparib BSI 61 paclitaxel poliglumex 61 follicular lymphomas 61 bortezomib refractory 61 metastatic CRC 61 CHOP chemotherapy 61 Campath alemtuzumab 61 ACTEMRA TM 61 Ceflatonin 61 CYPHER Stent 61 antiangiogenic therapy 61 complete cytogenetic response 61 IV tPA 61 metastatic carcinoid 61 cytoreductive nephrectomy 61 dose escalation phase 61 sorafenib 61 prior chemotherapy regimens 61 chemoradiotherapy 61 multiple myeloma MM 61 breast pancreatic 61 colorectal lung 61 PROLARIS 61 ISEL 61 FUSILEV enhances 61 Ozarelix 61 neoadjuvant chemotherapy 61 acute myeloid 61 ovarian endometrial 61 metastatic dermatofibrosarcoma protuberans DFSP 61 chemoradiation therapy 61 IL# PE#QQR 61 HIV coinfected 61 plus dexamethasone 61 adult chronic ITP 61 refractory indolent non 61 anti EGFR antibody 60 Xelox 60 OncoVEX GM CSF 60 CMV disease 60 AGILECT R 60 relapsed refractory AML 60 Insegia 60 HER2 amplified 60 adjuvant tamoxifen 60 KRAS mutant 60 ovarian carcinoma 60 5-FU/LV 60 leukemia lymphoma multiple myeloma 60 glufosfamide 60 pain palliation 60 malignant pleural mesothelioma MPM 60 diffuse gastric 60 gemcitabine cisplatin 60 Herceptin trastuzumab 60 R sorafenib tablets 60 metastatic androgen independent 60 FOLFOX 60 locoregional 60 neuroendocrine cancers 60 MKC# MT 60 hepatocellular carcinoma HCC 60 ER CHOP 60 SNT-MC#/idebenone 60 anti angiogenic therapy 60 Irinotecan 60 operable breast cancer 60 Ixempra 60 plus prednisone 60 postoperative chemotherapy 60 vemurafenib 60 mapatumumab 60 YONDELIS R 60 CIMZIA TM certolizumab pegol 60 pegylated liposomal doxorubicin PLD 60 chronic HCV 60 Navelbine ® 60 Mitomycin C 60 Torisel 60 nilotinib Tasigna ® 60 Myelodysplastic Syndrome MDS 60 docetaxel Taxotere 60 methotrexate monotherapy 60 tamoxifen Nolvadex ® 60 evaluating Nexavar 60 Vandetanib 60 cyclophosphamide methotrexate 60 prostate carcinoma 60 ixabepilone 60 HER2 positive cancers 60 paclitaxel cisplatin 60 refractory Hodgkin 60 bendamustine 60 Roche Xeloda 60 Squamous 60 Hycamtin 60 prostate cancer mCRPC 60 refractory multiple myeloma 60 LymphoStat B belimumab 60 alveolar rhabdomyosarcoma 60 non resectable metastatic 60 BARACLUDE ® 60 protease inhibitor PI 60 castration resistant hormone refractory 60 Pertuzumab 60 bevacizumab Avastin ® 60 fluorouracil 60 RhuDex ™ 60 chlorambucil 60 evaluable subjects 60 relapsed refractory multiple myeloma 60 SJIA 60 APTIVUS R 60 including eniluracil ADH 60 taxane chemotherapy administered 60 FOLFOX4 alone 60 neratinib 60 Elotuzumab 60 XELOX 60 refractory APL 60 CCyR 60 tyrosine kinase inhibitors TKIs 60 invasive candidiasis 60 biliary cancer 60 ZACTIMA TM ZD# 60 Patients Treated With 60 Zybrestat 60 radiochemotherapy 60 rheumatoid arthritis psoriatic arthritis 60 Pegintron 60 taxotere 60 HER2 positive 60 antibody MAb 60 p# biomarker 60 cancer mCRC 60 smoldering multiple myeloma 60 Xeloda capecitabine 60 metastatic CRPC 60 progression TTP 60 Metastatic breast cancer 60 relapsed AML 60 Pegylated Interferon 60 Platinol ® 60 pertuzumab 60 pazopanib 60 interferon ribavirin 60 cutaneous T 60 Dacogen injection 60 superficial basal cell carcinoma 60 Gliadel Wafer 60 TroVax ® 60 ancrod 60 clodronate 60 Engerix B 60 hepatic metastases 60 iniparib 60 Tarceva TM 60 Fludara 60 lenalidomide Revlimid R 60 hematopoietic cancers 60 essential thrombocythemia ET 60 pancreatic islet cell 60 cetuximab Erbitux ® 60 locoregional disease 60 HER2 negative 60 small lymphocytic lymphoma 60 interferon gamma 1b 60 Tesmilifene 60 Quinamed 60 Onrigin 60 SUTENT 60 carboplatin chemotherapy 60 partial remissions 60 Camptosar ® 60 achieved CCyR 60 AVONEX ® 60 hormone deprivation 60 DCVax ® Brain 60 daunorubicin 60 decitabine 60 chronic HBV 60 Juvenile Idiopathic Arthritis 60 pancreatic carcinoma 59 everolimus tablets 59 SIR Spheres 59 IMA# 59 thrombocytopenic 59 glioblastoma multiforme GBM 59 Aplidin 59 pomalidomide 59 Acute Myeloid Leukaemia AML 59 VELCADE melphalan 59 erlotinib Tarceva 59 alfa 2a 59 chronic plaque psoriasis 59 squamous cell histology 59 interferon beta therapy 59 Prednisone Against Refractory 59 PNH patients 59 amrubicin 59 minimally symptomatic metastatic castrate 59 Anthracycline 59 FOLFIRI 59 acetonide FA 59 nonmelanoma 59 recurrent malignant glioma 59 carboplatin paclitaxel 59 novel VDA molecule 59 debulking surgery 59 chemoresistant 59 metastatic basal cell 59 amoxicillin clavulanate 59 dosing cohort 59 metastatic HER2 negative 59 intravenous RSD# 59 Relapsed Refractory 59 Myelodysplastic syndromes MDS 59 abiraterone 59 ovarian breast 59 MCSP respectively 59 sunitinib Sutent 59 5-fluorouracil/leucovorin 59 Bevacizumab Avastin 59 Arranon 59 locoregional recurrence 59 Idiopathic pulmonary fibrosis 59 Gemcitabine 59 hepatocellular carcinomas 59 non squamous histology 59 BRAF inhibitor 59 Genasense ® 59 IIIA NSCLC 59 Cutaneous T 59 EOquin TM phase 59 hepatorenal syndrome 59 refractory CTCL 59 TELINTRA 59 Certolizumab pegol 59 Pegasys plus Copegus 59 Relapsing remitting MS 59 Afatinib 59 CLL SLL 59 vinca alkaloids 59 Vidaza ® 59 gp# vaccine 59 acyclovir Lauriad R 59 lymphoma CTCL 59 Alessandro Riva 59 invasive lobular carcinoma 59 TKI therapy 59 NovoTTF 59 FLT3 mutations 59 flutamide 59 bevacizumab Avastin 59 CINTREDEKIN BESUDOTOX 59 Bezielle 59 basiliximab 59 carcinoma HCC 59 Chronic Lymphocytic Leukemia CLL 59 HBeAg positive 59 nasopharyngeal carcinoma 59 imatinib Gleevec 59 mutated KRAS gene 59 cell carcinoma RCC 59 gefitinib 59 Zolinza 59 bladder ovarian 59 LEUKINE 59 surgical debulking 59 interferon alfa 59 IFN alfa 59 untreated multiple myeloma 59 remission induction 59 non splenectomised 59 resected pancreatic cancer 59 adjuvant radiotherapy 59 HCV genotype 1 59 chemo radiotherapy 59 anti angiogenic agents 59 candidemia 59 pegylated interferon alfa 2b 59 fibrate drugs 59 haematological cancers 59 chemoradiation 59 androgen independent 59 bladder cancers 59 mcg albinterferon alfa 2b 59 advanced HER2 positive 59 lymphocytic leukemia 59 Follicular Lymphoma 59 Chronic Myelogenous Leukemia CML 59 histological subtypes 59 TNF antagonist therapy 59 Pfizer Camptosar 59 de novo kidney transplant 59 achieved ACR# 59 receiving highly emetogenic 59 esthesioneuroblastoma rare form 59 chronic periodontitis 59 BRIM3 59 lung metastases 59 untreated CLL 59 follicular Non Hodgkin 59 Fludarabine 59 Paraplatin ® 59 surgically resectable 59 gemcitabine Gemzar 59 induce remission 59 refractory anaplastic astrocytoma 59 thoracoscopic lobectomy 59 carcinoid tumors 59 undergoing peritoneal dialysis 59 Phase #b/#a clinical 59 juvenile myelomonocytic leukemia 59 Acute myelogenous leukemia 59 XL# administered orally 59 coinfected patients 59 Myelodysplastic syndromes 59 HER2 positive tumors 59 kidney urologic 59 follicular lymphoma FL 59 EGFR inhibitors 59 Omacetaxine 59 CTAP# Capsules 59 Hazard Ratio 59 motesanib 59 dimensional conformal radiation 59 custirsen 59 lung colorectal 59 IIIB NSCLC 59 gastrointestinal stromal 59 GVAX Pancreas Vaccine 59 Seliciclib 59 K ras mutations 59 colorectal liver metastases 59 oxaliplatin Eloxatin 59 null responder 59 docetaxel Injection Concentrate 59 HGS ETR1 mapatumumab 59 elacytarabine 59 adjuvant therapies 59 cervical carcinoma 59 NATRECOR R 59 OnDose TM 59 carcinoid 59 ischemic cardiomyopathy 59 Tavocept 59 liposomal doxorubicin 59 Alocrest 59 epithelial ovarian 59 ToGA 59 Novartis Zometa 59 KRAS mutant tumors 59 cytokine refractory 59 proliferative retinopathy 59 Tumors shrank 59 OHR/AVR# 59 EGFR blockers 59 CR nPR 59 doublet chemotherapy 59 Glioblastoma Multiforme GBM 59 DEB# 59 Sutent sunitinib 59 Chronic myeloid leukemia 59 allogeneic bone marrow 59 chronic myocardial ischemia 59 genotypic resistance 59 letrozole Femara 59 fluoropyrimidine 59 Proleukin 59 Gleevec imatinib 59 EndoTAGTM 1 59 Acute Myelogenous Leukemia AML 59 sarcomatoid 59 LUX Lung 59 galiximab 59 antiretroviral naive 58 SCIg 58 Ophena TM 58 lupus nephritis 58 soft tissue sarcomas 58 tamoxifen therapy 58 refractory acute promyelocytic 58 CTEPH 58 superficial bladder cancer 58 recurrent squamous cell carcinoma 58 Taxotere docetaxel 58 Rituxan rituximab 58 nonmelanoma skin cancers 58 Kit CD# positive 58 peginterferon alpha 2a 58 Golimumab 58 mutated KRAS 58 COPEGUS ribavirin 58 cell lymphoma CTCL 58 radiolabeled TM# 58 opioid induced constipation OIC 58 Dacogen decitabine 58 GISTs 58 epirubicin cyclophosphamide 58 patientswith 58 cetuximab Erbitux R 58 capecitabine Xeloda 58 enzastaurin 58 situ CIS 58 advanced pancreatic neuroendocrine 58 pleural mesothelioma 58 Glioblastoma multiforme GBM 58 pelvic malignancies 58 Axitinib 58 indolent NHL 58 recurrent metastatic ovarian cancer 58 acute myelogenous 58 castration resistant prostate cancer 58 AEG# 58 azacitidine 58 histologic subtype 58 System IPSS 58 ocular melanoma 58 FOLFOX regimen 58 systemic anaplastic large 58 GW# [003] 58 leukemia CLL 58 osteolytic bone disease 58 trastuzumab Herceptin ® 58 Halaven 58 Free Survival PFS 58 Lucrin 58 refractory DLBCL 58 toenail onychomycosis 58 evaluating mipomersen 58 ® lenalidomide 58 EGFR tyrosine kinase inhibitors 58 hepatitis C HCV 58 AVASTIN 58 herpetic keratitis 58 phase IIb clinical 58 curative resection 58 coinfected 58 paclitaxel chemotherapy 58 interferon therapy 58 XL# SAR# 58 aflibercept 58 Neoadjuvant 58 EGFR mutations 58 undergone radical prostatectomy 58 castration resistant 58 Eli Lilly Gemzar 58 refractory SCLC 58 EFAPROXYN 58 nonnucleoside reverse transcriptase inhibitors 58 nodal metastasis 58 pegylated interferon alfa 58 budesonide foam 58 phase IIb trial 58 Ranibizumab 58 International Prognostic Scoring 58 imatinib mesylate Gleevec 58 Cabazitaxel 58 myeloablative 58 lapatinib Tykerb 58 HBeAg positive patients 58 Hsp# Inhibitor 58 acute myelogenous leukemia AML 58 myelogenous leukemia 58 Trastuzumab DM1 58 RhuDex R 58 chronic lymphocytic leukemia CLL 58 concurrent ITP 58 Median PFS 58 afatinib 58 pancreatic prostate 58 metastatic colon cancer 58 Tyrosine Kinase Inhibitors 58 vismodegib 58 Novartis Afinitor 58 TEMODAL 58 farletuzumab 58 pT3 58 efaproxiral 58 inoperable pancreatic cancer 58 lymphoma multiple myeloma 58 metastatic NSCLC 58 advanced adenomas 58 Acute Coronary Syndromes ACS 58 pediatric Crohn disease 58 Epithelial ovarian cancer 58 T1a 58 phase III isavuconazole 58 ximelagatran 58 Virulizin ® 58 thalidomide Thalomid 58 alpha1 antitrypsin deficiency 58 Taxotere ® 58 cytogenetic responses 58 myelodysplastic myeloproliferative diseases 58 metaglidasen 58 idiopathic pulmonary fibrosis IPF 58 sargramostim 58 tolevamer 58 receiving prophylactic anticoagulation 58 adverse cytogenetics 58 RhuDex ® 58 Valcyte tablets 58 nucleoside naive 58 alvespimycin 58 bone marrow reticulin deposition 58 Evoltra ® 58 Subgroup analysis 58 MCyR 58 Troxatyl 58 cell lung cancer 58 PEG interferon 58 Pegasys peginterferon alfa 2a 58 SinuNase TM 58 Basal cell 58 nasopharyngeal cancer 58 lenalidomide dexamethasone 58 Combination REOLYSIN R 58 chemoembolization 58 Cell Lymphoma CTCL 58 gallium nitrate 58 refractory prostate cancer 58 Median progression 58 ipsilateral breast 58 Soft Tissue Sarcoma 58 treatment naive genotype 58 chemosensitizer 58 pancreatic lung 58 malignant neoplasm 58 pegylated interferons 58 trastuzumab DM1 T DM1 58 Femara letrozole 58 nondiabetic patients 58 cutaneous melanoma 58 YERVOY 58 highly emetogenic 58 hormone receptor negative 58 HBeAg negative patients 58 cytologically confirmed 58 Chronic lymphocytic leukemia CLL 58 dose cytarabine 58 Glufosfamide 58 dalteparin 58 ASA# 58 androgen deprivation 58 hematologic disorders 58 thetreatment 58 curative therapy 58 Relapsed Multiple Myeloma 58 pediatric malignancies 58 drug figitumumab 58 Castration Resistant Prostate Cancer 58 Intravenous CP 58 irinotecan doxorubicin oxaliplatin paclitaxel 58 HER2 positive breast cancer 58 membranous nephritis 58 Anaplastic 58 hormone refractory prostate cancer 58 relapsing multiple sclerosis 58 immunomodulatory therapy 58 chronic HCV infection 58 phase IIb study 58 HCV genotype 58 Acute Myelogenous Leukemia 58 anaplastic astrocytoma 58 HBeAg + 58 tyrosine kinase inhibitors 58 rALLy 58 vinflunine 58 IRESSA 58 Gleevec Glivec 58 benign prostatic hypertrophy BPH 58 ovarian prostate 58 Phase #/#a trial 58 adjuvant chemotherapy 58 Wilms tumors 58 Xanafide 58 pegylated interferon alpha 2a 58 Colon polyps 58 exemestane Aromasin 58 HER2 positive breast 58 NYHA Class II 58 skeletal metastases 58 MIRAPEX ER 58 BCR ABL inhibitor 58 infliximab monotherapy 58 Campath ® 58 evaluable 58 relapsed Hodgkin lymphoma 58 huN# DM1 58 metastatic breast 58 eosinophilic asthma 58 Sapacitabine 58 Motesanib 58 interferon alfa 2a 58 baminercept 58 induced anemia 58 PegIFN RBV 58 p#HER# positive 58 methotrexate therapy 58 Papillary 58 goserelin 58 metastatic ovarian cancer 58 ductal breast cancer 58 autologous SCT 58 gastrin analogue TT 58 GAMMAGARD 58 refractory metastatic colorectal cancer 58 CRLX# 58 neoadjuvant 58 sustained virological response 58 CAMMS# 58 non valvular atrial 58 PegIntron 58 Glioblastoma multiforme 58 leukemia myeloma 58 ChronVac C R 58 long acting bronchodilator 58 naïve HCV 58 subependymal giant cell 58 CIMZIA ™ 57 metastatic neuroendocrine tumors 57 Opportunistic infections 57 mycosis fungoides 57 HGS# 57 assessing T DM1 57 AVODART 57 AIR CF1 57 Peginterferon 57 Voraxaze ™ 57 precancerous cervical lesions 57 Cell Lung Cancer 57 anthracycline therapy 57 Phase Ib IIa 57 untreated metastatic colorectal 57 ovarian cervical 57 KRAS status 57 de novo AML 57 PLX STROKE targeting 57 Telcyta 57 Novartis Gleevec 57 lymphoma Hodgkin lymphoma 57 5 FU leucovorin 57 Gemzar gemcitabine 57 LHON 57 huC# DM4 57 sunitinib 57 mitoxantrone 57 HIV HCV coinfected 57 Proellex TM 57 pT2 57 Diamyd ® 57 dengue haemorrhagic fever DHF 57 elotuzumab 57 docetaxel prednisone 57 Uterine cancer 57 Allovectin 7 R 57 adalimumab Humira 57 refractory ALCL 57 ribavirin RBV 57 prostate carcinomas